Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials
Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise control of the psychedelic state and the ability to halt treatment if adverse events occur, enhancing patient safety.
Phase 1b Achievements
TRP-8803 was well-tolerated across all tested doses—low, mid and high—demonstrating its safety profile. The study identified optimal doses and infusion rates that maintained psilocin blood …